Why VC Funding Rounds Do Not Measure Deep Tech Maturity

Maria Ksenia Witte

17. Sept.

3 Min. Lesezeit

Seed. Series A. Series B. Growth. Late stage.

These labels are so familiar that they have started to look like a development model. The sequence feels orderly: raise capital, prove something, grow and scale.

For complex technologies, that sequence is often a poor description of what is happening inside the company. Funding rounds describe transactions. They do not reliably describe technical maturity, regulatory readiness, production capability, customer integration or organisational independence.

The same funding round can hide radically different companies

A Series A software company may have a deployable product, recurring customers and low marginal delivery cost. A Series A diagnostics company may still depend on analytical validation, clinical evidence, reimbursement and manufacturing transfer. An advanced-materials company at the same financing stage may have strong laboratory performance but no qualified production route, accepted specification or customer willing to absorb integration risk.

The financing label makes these companies look comparable precisely when their decisive constraints are not.

What funding rounds are designed to do

Staged financing exists for good reasons. Investors do not fund the entire uncertain life of a venture at inception. Capital is released around milestones, ownership is repriced, governance rights change and stop options are preserved. New investors can enter with different expertise and risk tolerance.

The problem is category leakage: language created to coordinate capital becomes shorthand for the state of the organisation. A financing stage begins to imply readiness outside the financing transaction.

Complex technology companies do not move through a universal ladder. They occupy configurations shaped by scientific evidence, regulation, production, customers, people and capital. A company can be advanced in one dimension and highly dependent in another.

How stage labels create fake confidence

Once a company is called a scale-up or Series B venture, expectations attach to the label. Management is expected to expand, professionalise and accelerate sales. The category starts prescribing behaviour.

This creates pressure to interpret ambiguity in the direction of progress. More sales activity is read as repeatable delivery. More employees are read as organisational capability. More customer interest is read as adoption. Yet visible growth can coexist with unresolved dependencies.

When targets are missed, leaders often add effort inside the expected model instead of questioning whether the model describes the company accurately. A structural problem is treated as an execution problem.

The consequences for investors, programmes and corporates

For investors, the confusion weakens portfolio visibility. A round can extend runway without resolving the dependency that determines progress. Companies may finance commercial expansion before qualification is complete or build production capacity before demand is decision-grade.

For accelerator and support programmes, stage labels create cohort-design errors. Companies are grouped by capital raised or revenue despite needing different interventions. Everyone receives investor readiness, mentoring and corporate introductions while the specific transition remains unsupported.

For corporates, a well-funded venture can still be an unready supplier. Documentation, process stability, liability allocation and implementation capacity may be missing. Venture maturity and vendor readiness are not the same.

For founders, the label can be personally destructive. When the system says a company should already be scaling, structural incompleteness begins to feel like leadership failure. The response is often more visible activity—and worse information.

Why a universal maturity model is not enough

Replacing funding stages with one comprehensive maturity score sounds attractive. It can still reproduce the same mistake. Different technologies reach value through different routes. Some depend on regulation and physical scale-up; others on licensing, data access or integration into existing infrastructure.

Maturity must be interpreted relative to purpose. A company can be ready for one partnership and unready for another. It can be investable while unsuitable as a critical supplier. It can create valuable intellectual property without having a durable operating model.

This is closely related to why valuation events should not be mistaken for value-creation models. Transactions create orientation, not a complete map.

Assess transitions, not labels

The more useful questions are: which transition is the company attempting, which constraints are coupled, who owns each decision and what evidence makes the next commitment rational?

That framing supports better investment, procurement, partnership and programme decisions. It also reveals when the next round would accelerate the right work—and when it would scale an architecture that is not ready.

I develop decision-specific transition reviews for institutions evaluating deep tech ventures and for founders building commercialization pathways. The work does not replace technical, legal or financial diligence. It connects the combined evidence to the commitment actually under consideration.

A funding round is a milestone, not a maturity model

The most dangerous company is not necessarily the least mature. It is the company whose visible stage implies a maturity its operating architecture does not support.